Ebglyss Clears Hand and Foot Eczema in 53% of Patients at 16 Weeks
ADtouch trial: 53% of hand and foot eczema patients on lebrikizumab reached clear skin at 16 weeks vs 27% on placebo; Eli Lilly seeks FDA label update.
Topic
Adtouch Trial
Topic
Topic
Topic
ADtouch trial: 53% of hand and foot eczema patients on lebrikizumab reached clear skin at 16 weeks vs 27% on placebo; Eli Lilly seeks FDA label update.